Jasper Therapeutics, Inc. (JSPR) has disclosed a new risk, in the Innovation / R&D category.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Jasper Therapeutics, Inc. faces significant business risks due to potential delays in the commencement or completion of clinical trials, which could escalate drug development costs and hinder strategic collaborations. These delays may arise from various factors, such as regulatory approval challenges, supply chain disruptions, and recruitment difficulties, which could ultimately impact the company’s ability to generate product revenues. Recent issues in the BEACON study, including atypical results and halted enrollment in the ETESIAN study, underscore the potential for increased costs and slowed development timelines. Such setbacks could allow competitors to gain market advantage and shorten Jasper’s patent protection period, thereby adversely affecting its business and financial prospects.
Overall, Wall Street has a Moderate Buy consensus rating on JSPR stock based on 7 Buys and 4 Holds.
To learn more about Jasper Therapeutics, Inc.’s risk factors, click here.